Table 1.

Baseline characteristics of the untreated and pre-existing statin use groups

	Untreated N=19	Pre-existing Statin Use N=12	P–value†
Female, n (%)*	11 (58%)	3 (25%)	0.14
Age (years), median (IQR)‡	60 (54, 72)	62 (59, 66)	0.72
Admission NIHSS, median (IQR)	16 (10, 18)	18 (13, 20)	0.60
tPA treatment, n (%)*	12 (63%)	11 (92%)	0.11
Volume tp1 perfusion deficit (ml), median (IQR)	62 (23,116)	50 (17,88)	0.73
Time between tp1 and tp2 (min), median (IQR)	215 (187, 239)	195 (159, 223)	0.19
Admission MAP (mmHg), median (IQR)	110 (94, 145)	112 (108, 116)	0.86
Admission Glucose (mg/dl), median (IQR)	128 (101, 146)	145 (121, 165)	0.26
LDL (mg/dl), median (IQR)	100 (73, 119)	72 (59, 103)	0.16
African-American, n (%)*	6 (32%)	4 (33%)	1.0
Time from tPA-bolus to tp1 (min), median (IQR)	44 (23, 54)	50 (41, 60)	0.32
Absolute Volume Reperfusion (ml), median (IQR)	6 (3, 13)	12 (7,31)	0.06
Volume DWI lesion tp1 (ml), median (IQR)	32 (7, 55)	15 (8, 30)	0.51
Onset-to-needle time (min), median (IQR)	110 (99, 121)	110 (101, 133)	0.65
History of Hypertension, n (%)*	15 (79%)	10 (83%)	1.0
History of Diabetes, n (%)*	7 (37%)	6 (50%)	0.71
History of Congestive Heart Failure, n (%)*	5 (26%)	1 (8%)	0.36
Current Tobacco Use, n (%)*	7 (37%)	5 (42%)	1.0
History of Coronary Artery Disease, n (%)*	2 (10%)	6 (50%)	0.03
History of Stroke or TIA, n (%)*	2 (10%)	4 (33%)	0.17

^†Wilcoxon Rank Sum Test unless indicated by (*).

^*Fisher’s Exact Test was used for assessing difference in frequencies between two groups.

^‡Due to small sample size, results are expressed as median and inter-quartile range (IQR).

NIHSS = NIH Stroke Scale; MAP = Mean Arterial Pressure; LDL=Low Density Lipoprotein; DWI = Diffusion Weighted Imaging; TIA = Transient Ischemic Attack